Previous 10 | Next 10 |
MiMedx Group press release ( NASDAQ: MDXG ): Q4 GAAP EPS of -$0.02. Revenue of $74.38M (+10.4% Y/Y). For further details see: MiMedx Group GAAP EPS of -$0.02, revenue of $74.38M
Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Strong Contributions from Sales to the Surgical Market Initiated the First of Two Registrational Clinical Trials for micronized d...
MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended D...
Wound care company MiMedx Group ( NASDAQ: MDXG ) said on Monday that Joseph Capper, a MedTech and Life Sciences veteran with a track record in M&A, has been appointed as its chief executive officer with immediate effect. Todd Newton, who has functioned as the company’s inte...
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and lea...
MiMedx ( NASDAQ: MDXG ) said it continues to expect Q4 net sales to be in the ranges of $73M to $76M vs. estimates of $74.53M The company also continues to expect full year revenue of $266M to $269M vs. $268M consensus, which remains unchanged from the outlook provided during the ...
Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of recently published Medicare reimbursement proposals on its wound care products MARI...
MiMedx Group ( NASDAQ: MDXG ) on Wednesday said it had entered into an exclusive distribution agreement with Japan's Gunze Medical for sales of its EPIFIX product. MDXG stock gained 7.3% to $3.22 after hours. MDXG's EPIFIX is a placental tissue allograft that can be used t...
MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX MARIETTA, Ga. and OSAKA, Japan, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer...
MiMedx Group ( NASDAQ: MDXG ) has appointed Ricci S. Whitlow as COO. Most recently she served as President, Clinical Supply Services at Catalent. For further details see: MiMedx appoints Ricci S. Whitlow as Chief Operating Officer
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 07:00:07 ET Ross Osborn from Cantor Fitzgerald issued a price target of $11.00 for MDXG on 2024-07-02 06:15:00. The adjusted price target was set to $11.00. At the time of the announcement, MDXG was trading at $6.7. The overall price target consensus is at $10...
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company’s Senior Vice President, Sales si...
2024-06-13 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...